Herr Amy E. 4
4 · BIO-TECHNE Corp · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Bio-Techne (TECH) Director Amy E. Herr Sells 1,976 Shares
What Happened
Amy E. Herr, a director of Bio-Techne Corporation (TECH), sold 1,976 shares of company stock in open-market/private sales on February 17, 2026. The reported weighted-average price was $59.10 per share, for total proceeds of approximately $116,791. This was a sale (disposition), which is commonly routine insider selling and does not, by itself, indicate a change in company outlook.
Key Details
- Transaction date: 2026-02-17; filing date (Form 4): 2026-02-19 (appears timely — within the usual 2-business-day window).
- Shares sold: 1,976; weighted-average price: $59.10; aggregate proceeds: $116,791.
- Price range: transactions occurred at prices between $59.091 and $59.1390; the $59.10 figure is a weighted average (Footnote F1).
- Shares owned after the transaction: not specified in the excerpt provided — see the full Form 4 for post-transaction holdings.
- Notable footnotes: filing lists multiple outstanding awards and vesting schedules (RSUs and stock options) for the reporting person, with vesting dates through 2026–2029 (see Footnotes F2–F13). Footnote F8 clarifies each RSU equals one share.
- Transaction code: S = Sale (disposition).
Context
- This filing reports a sale, not a purchase or exercise. Sales by directors can be routine (liquidity, diversification, tax planning) and do not by themselves imply insider pessimism.
- The filing also documents outstanding restricted stock units and options that will vest on various future dates; those are separate from this sale.
- For full details on holdings after the sale and the exact per-trade breakdown within the reported price range, consult the complete Form 4 (the filer offers to provide the number of shares sold at each separate price upon request, per F1).
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
Herr Amy E.
Director
Transactions
- Sale
Common Stock
[F1]2026-02-17$59.10/sh−1,976$116,791→ 200 total(indirect: By significant other)
Holdings
- 2,680
Common Stock
- 2,415
Stock Option (Right to Buy)
Exercise: $72.05From: 2025-10-24Exp: 2035-02-03→ Common Stock (2,415 underlying) - 3,777
Stock Option (Right to Buy)
[F2]Exercise: $60.96Exp: 2035-10-30→ Common Stock (3,777 underlying) - 6,636(indirect: By significant other)
Stock Option (Right to Buy)
[F3]Exercise: $47.60Exp: 2026-08-07→ Common Stock (6,636 underlying) - 4,472(indirect: By significant other)
Stock Option (Right to Buy)
[F3]Exercise: $66.97Exp: 2027-08-05→ Common Stock (4,472 underlying) - 2,076(indirect: By significant other)
Stock Option (Right to Buy)
[F3]Exercise: $120.46Exp: 2028-08-06→ Common Stock (2,076 underlying) - 2,104(indirect: By significant other)
Stock Option (Right to Buy)
[F4]Exercise: $94.52Exp: 2029-08-15→ Common Stock (2,104 underlying) - 1,084(indirect: By significant other)
Stock Option (Right to Buy)
[F5]Exercise: $84.61Exp: 2030-08-15→ Common Stock (1,084 underlying) - 1,468(indirect: By significant other)
Stock Option (Right to Buy)
[F6]Exercise: $74.91Exp: 2034-08-15→ Common Stock (1,468 underlying) - 344(indirect: By significant other)
Stock Option (Right to Buy)
[F7]Exercise: $72.05Exp: 2035-02-03→ Common Stock (344 underlying) - 118(indirect: By significant other)
Restricted Stock Units
[F8][F9]→ Common Stock (118 underlying) - 320(indirect: By significant other)
Restricted Stock Units
[F8][F10][F9]→ Common Stock (320 underlying) - 77(indirect: By significant other)
Restricted Stock Units
[F8][F11][F10]→ Common Stock (77 underlying) - 932(indirect: By significant other)
Restricted Stock Units
[F8][F12][F11]→ Common Stock (932 underlying) - 2,735(indirect: By significant other)
Stock Option (Right to Buy)
[F13]Exercise: $53.60Exp: 2035-08-15→ Common Stock (2,735 underlying)
Footnotes (13)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F10]160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- [F11]38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
- [F12]311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- [F13]Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
- [F2]This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- [F3]Fully vested.
- [F4]Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
- [F5]Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- [F6]Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- [F7]Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- [F8]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- [F9]118 restricted stock units vest on 8/15/2026.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed|2026-02-19